One of them sells billing. For us, billing is one of eight.
XiFin Pharmacy Solutions is the former OmniSYS, and it carries one of the longest track records in pharmacy medical billing anywhere. If your problem is billing muscle at scale, this is a serious company and you should treat it as one. The question worth asking is whether billing is actually the whole of your problem.
A quarter century of pharmacy medical billing does not happen by accident.
Genuine chain and health system scale
XiFin announced the OmniSYS acquisition as a provider "serving four of the top five national chains", and the pharmacy division has stated a reach of over 30,000 pharmacies across multiple releases. In 2026 the company states it is a business partner to more than half of pharmacies in the United States. Those are XiFin's own figures, published without a stated methodology, and we report them as their claims rather than as findings of ours. Either way, this is not a startup.
Medical billing as the core discipline, not an add-on
The pharmacy division describes itself in terms of medical billing, pharmacy workflow enabled solutions and patient engagement software. OmniSYS also built Strand-Rx, which it described as the industry's first pharmacy-specific electronic health record, and said it supported over 1.2 million pharmacist-provided clinical encounters in a year. Very few vendors in this market have that much clinical billing history behind them.
Real RCM lineage, from diagnostics
XiFin's heritage is revenue cycle management for laboratories and diagnostic providers, and its own description is of technology that facilitates connectivity and workflow automation across diagnostic, retail pharmacy and oncology markets. Denials work, appeals and payor response interpretation are native disciplines there rather than things a pharmacy vendor learned late.
Rate transparency as a first-class problem
XiFin introduced a Payor Rate Transparency Monitor in December 2023, comparing contracted rates published by UnitedHealthcare, Aetna and Cigna out of Transparency in Coverage data. To be exact, because it matters: that product is for diagnostic providers and was later extended to radiology, not a pharmacy tool. We credit it anyway, because building it at all says something correct about where a company thinks reimbursement leverage comes from.
Billing is their product. Here it is one of eight on one connection.
This is a difference in shape, not in quality. A pharmacy that buys billing gets billing, and if that is the gap, buying the specialist is a rational purchase. But the fill that adjudicated below your acquisition cost this morning is not a billing problem, the two hundred claim audit letter is not a billing problem, and the prior authorization that has been open for nine days is not a billing problem. Each of those needs its own tool, its own login, its own contract and its own integration, or it needs to be in the same system as the billing. We built the second thing: eight products on one event spine, so the claim, the cost, the encounter and the evidence are already joined before anyone asks a question that needs all four.
What each side publishes, side by side.
XiFin's pharmacy capability pages render client-side and could not be retrieved, so their column is drawn from press releases, an event page and their own sitemap. Where that leaves a genuine gap, the cell says so.
| Capability | Attergo | XiFin Pharmacy Solutions |
|---|---|---|
| Pharmacy medical billing | Yes. Encounter to 837P to 835, with eligibility checked before the service and denials returned as work items carrying the payer reason. | Yes, and it is the core of the offering. Named in the pharmacy division description as medical billing alongside workflow and patient engagement software. |
| Automated denial prioritization and appeal generation | No equivalent. Denials arrive as work items carrying the payer reason, and appeal evidence is already bound to the claim, but we ship no model that ranks exceptions or drafts an appeal for you. | Yes, and further than we go. A XiFin event page describes AI-driven error and denial prioritization, payor response interpretation, and an Appeals Agent producing an appeals package aligned with payor policy. |
| Per-fill margin against your acquisition cost | Yes. Every claim priced seconds after adjudication against your own wholesaler invoice, with the cost source labeled and unknown cost never shown as profit. | Not stated in any material we could retrieve. |
| PBM audit evidence and response packages | Yes. Every event archived as it arrived, documents bound to their claim on the day, and a response package exported from a pasted claim list. | Not stated in any material we could retrieve. |
| Electronic prior authorization | Yes, as one of the eight products, started by the rejection itself and tracked to renewal. | Not stated in any material we could retrieve. |
| Purchasing, dead stock and DSCSA | Yes, and the buying is margin-aware because the claims data is in the same system. | Not stated in any material we could retrieve. |
| Published pricing | Yes. Flat, per store, on the pricing page, never a percentage of collections. | Not published. |
| Scale and installed base | One production dispensing integration today, PioneerRx, stated plainly on the integrations page. We are the smaller company here and say so. | Substantially larger. XiFin states more than half of United States pharmacies as partners and over 30,000 pharmacies reached. |
Every entry in the XiFin Pharmacy Solutions column is drawn from the pages listed at the foot of this page. Where their own materials do not state a capability, the cell says so rather than guessing, because an absence of marketing copy is not evidence of an absence of capability.
Two honest recommendations.
Choose XiFin Pharmacy Solutions if
you are a large chain, a health system outpatient operation or a specialty pharmacy with an existing revenue cycle department, and what you actually need is outsourced billing muscle at volume: a partner who has processed medical claims for pharmacy at national scale for two decades, who already sits inside enterprise procurement, and whose denials and appeals practice is mature. If billing throughput is the constraint and the rest of your stack is settled, buying the specialist is the correct decision and a suite will not beat them at it.
Choose Attergo if
billing is one of several things going wrong at once, and you would rather not solve them one vendor at a time. If you also need to know which fills lost money this morning, to answer a PBM audit without three weeks of archaeology, to stop losing prior authorizations to statelessness, and to buy inventory with the claims data in view, then the joins between those things are the product, and that is what one platform and one connection gives you that a billing specialist structurally cannot.
The product that carries most of this weight on our side is Attergo Billing, and it is one of eight on a single connection.
Every claim above traces to their own words.
- XiFin press release, 18 January 2022: OmniSYS acquisition, top five chains, Strand-Rx and 1.2 million clinical encounters
- XiFin press release, 4 April 2022: "OmniSYS, a XiFin Company", and the 30,000 pharmacies figure
- XiFin press release, 6 June 2024: OmniSYS as "the pharmacy division of XiFin, Inc.", medical billing and CareALERTS
- XiFin press release, 18 December 2023: the Payor Rate Transparency Monitor, for diagnostic providers
- XiFin press release, 22 May 2026: "a business partner to more than half of pharmacies across the United States"
- XiFin event page: denial prioritization, Appeals Agent and payor response interpretation
What we could not verify
XiFin's pharmacy pages under xifin.com render their body content client-side, and every attempt to retrieve them returned only the page shell. That means we could not confirm, and therefore do not assert anything about, their payer connectivity specifics, claim submission mechanics, patient statement products or reporting and analytics products. The rows above marked as not stated should be read as "we could not find it published", not as "they do not do it". If you are evaluating XiFin, ask them these questions directly and take their answer over our table. We would rather be corrected than guess, and the address at the top of this section is the fastest way to correct us.
See both columns run against your own claims.
Thirty minutes, one facility, a read-only connection and credentials you can revoke. We come back with what your own last month actually cost you.
Comparison based on publicly available information as of 2 August 2026. See something outdated? Tell us and we'll fix it. sales@attergo.com